Many neoplastic cell lines secrete insulin-like growth factor binding proteins (IGFBPs). The physiological role of these proteins is incompletely characterized; under various conditions IGFBPs have been observed to either enhance or inhibit the biological activity of insulin-like growth factors. MCF7 human breast cancer cells are known to be mitogenically responsive to insulin-like growth factors and estrogens, to secrete several IGFBPs, including BP-2, BP-4 and BP-5, and to be growth inhibited by antiestrogens. We report here that the pure antiestrogen ICI 182,780 and, to a lesser extent, the commonly used drug tamoxifen significantly increase levels of a M, 43,000-46,000 IGFBP (BP-3) and significantly reduce levels of a M, 24,000 IGFBP (B...
To gain insight into the mechanisms involved in the cross-talk between IGF-1 receptor (IGF-1R) and e...
From the MCF-7 cell line we have developed, a human mammary cancer cell subline with the same karyot...
Tamoxifen (TAM) remains the adjuvant therapy of choice for pre-menopausal women with ERα-positive br...
Insulin-like growth factors (lGFs) are potent mitogens for breast cancer cells. Although IGF-binding...
MCF-7 human breast cancer cells are commonly used to model tissues responsive to estrogens and antie...
The synthesis and secretion of insulin-like growth factor binding proteins (IGFBPs) were studied in ...
We have recently demonstrated that exposure of MCF7 cells to antiestrogens in vitro results in both ...
This article is hosted on a website external to the CBCRA Open Access Archive. Selecting “View/Open...
This article is hosted on a website external to the CBCRA Open Access Archive. Selecting “View/Open...
Differences in insulin-like growth factor binding proteins (IGFBPs) expressed within estrogen recept...
Insulin-like growth factors (IGFs) are known to have potent antiapoptotic activity. The antiestrogen...
The development of tamoxifen resistance (TR) in oestrogen-dependent breast cancer (BC) is a therapeu...
The development of tamoxifen resistance (TamR) in oestrogen receptor positive (ER+) breast cancer is...
From the MCF-7 cell line we have developed, a human mammary cancer cell subline with the same karyot...
From the MCF-7 cell line we have developed, a human mammary cancer cell subline with the same karyot...
To gain insight into the mechanisms involved in the cross-talk between IGF-1 receptor (IGF-1R) and e...
From the MCF-7 cell line we have developed, a human mammary cancer cell subline with the same karyot...
Tamoxifen (TAM) remains the adjuvant therapy of choice for pre-menopausal women with ERα-positive br...
Insulin-like growth factors (lGFs) are potent mitogens for breast cancer cells. Although IGF-binding...
MCF-7 human breast cancer cells are commonly used to model tissues responsive to estrogens and antie...
The synthesis and secretion of insulin-like growth factor binding proteins (IGFBPs) were studied in ...
We have recently demonstrated that exposure of MCF7 cells to antiestrogens in vitro results in both ...
This article is hosted on a website external to the CBCRA Open Access Archive. Selecting “View/Open...
This article is hosted on a website external to the CBCRA Open Access Archive. Selecting “View/Open...
Differences in insulin-like growth factor binding proteins (IGFBPs) expressed within estrogen recept...
Insulin-like growth factors (IGFs) are known to have potent antiapoptotic activity. The antiestrogen...
The development of tamoxifen resistance (TR) in oestrogen-dependent breast cancer (BC) is a therapeu...
The development of tamoxifen resistance (TamR) in oestrogen receptor positive (ER+) breast cancer is...
From the MCF-7 cell line we have developed, a human mammary cancer cell subline with the same karyot...
From the MCF-7 cell line we have developed, a human mammary cancer cell subline with the same karyot...
To gain insight into the mechanisms involved in the cross-talk between IGF-1 receptor (IGF-1R) and e...
From the MCF-7 cell line we have developed, a human mammary cancer cell subline with the same karyot...
Tamoxifen (TAM) remains the adjuvant therapy of choice for pre-menopausal women with ERα-positive br...